The effectiveness of COVID-19 vaccines in Latin America, 2021: a multicenter regional case–control study

dc.creatorKahn, Rebecca
dc.creatorJanusz, Cara B.
dc.creatorCastro, Marcia C.
dc.creatorMatos, Aline da Rocha
dc.creatorDomingues, Carla
dc.creatorPonmattam, Jamie
dc.creatorRey-Benito, Gloria
dc.creatorToscano, Cristiana M.
dc.creatorOliveira, Lucia Helena de
dc.creatorRegional COVID-19 VE in Adults Study Working Group
dc.date2023-05-26T14:09:08Z
dc.date2023-05-26T14:09:08Z
dc.date2023
dc.date.accessioned2023-09-26T20:44:44Z
dc.date.available2023-09-26T20:44:44Z
dc.identifierKHAN, Rebecca et al. The effectiveness of COVID-19 vaccines in Latin America, 2021: a multicenter regional case–control study. The Lancet Regional Health - Americas. v.20: 100474, p. 1 - 12, 2023.
dc.identifier2667-193X
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/58743
dc.identifier10. 1016/j.lana.2023. 100474
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8863104
dc.descriptionFunding This study was funded by the Pan-American Health Organization (PAHO, World Health Organization (WHO)). PAHO convened and led the study implementation.
dc.descriptionSummary Background As of September 2022, nearly 1.3 billion doses of COVID-19 vaccine products have been administered in Latin America and the Caribbean, where 27% of global COVID-19 deaths have occurred. This study aimed to estimate the effectiveness of COVID-19 vaccines against lab-confirmed COVID-19 related hospitalizations and deaths among adults in Argentina, Brazil, Chile, and Colombia. Methods Using a test-negative case control design, we evaluated the effectiveness of a primary vaccination series considering six COVID-19 vaccine products (Sputnik V, mRNA-1273, CoronaVac, ChAdOx1, BNT162b2, Ad26.COV2.S) against lab-confirmed COVID-19 hospitalizations and deaths among 83,708 hospitalized adults from February–December, 2021. Data from hospitalization records, COVID surveillance, and vaccination registries were used. Vaccine effectiveness was estimated using logistic regression ((1-OR) x 100). Findings The average age of participants was 56.7 (SD = 17.5), and 45,894 (54.8%) were male. Adjusted VE (aVE) estimates for full vaccination against hospitalization were 82% for mRNA-1273 (95% confidence interval (CI) = −30 to 98%), 76% (71%–81%) for BNT162b2, 65% (61–68%) for ChAdOx1, 57% (10–79%) for Sputnik V, 53% (50–56%) for CoronaVac, and 46% (23–62%) for Ad26.COV2.S. Estimates, particularly for CoronaVac, varied by variant. Decreasing aVE was estimated as age increased, particularly for CoronaVac and ChAdOx1. aVE estimates against death were generally higher, with 100% (CI not estimated) for mRNA-1273, 82% (69–90%) for BNT162b2, 73% (69–77%) for ChAdOx1, 65% (60–67%) for CoronaVac, 38% (−75 to 78%) for Sputnik V, 6% (−58 to 44%) for Ad26.COV2.S.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier Ltd.
dc.rightsopen access
dc.subjectVacinação COVID-19
dc.subjectEficácia da vacina
dc.subjectControle de caso
dc.subjectTeste negativo
dc.subjectBrasil
dc.subjectChile
dc.subjectArgentina
dc.subjectColômbia
dc.subjectCOVID-19 vaccination
dc.subjectVaccine effectiveness
dc.subjectCase–control
dc.subjectTest-negative
dc.subjectBrazil
dc.subjectChile
dc.subjectArgentina
dc.subjectColombia
dc.titleThe effectiveness of COVID-19 vaccines in Latin America, 2021: a multicenter regional case–control study
dc.typeArticle


Este ítem pertenece a la siguiente institución